Results 191 to 200 of about 507,240 (308)

Model‐Informed Dose Optimization of Anakinra in Preterm Neonates Implications for Safe and Effective Dosing

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Anakinra, an interleukin‐1 receptor antagonist, shows promise for reducing inflammatory complications of premature birth. However, the pharmacokinetics (PK) of anakinra in neonates has not been characterized, limiting evidence‐based dosing. This study aimed to develop a population PK model for anakinra to guide dosing in preterm neonates.
Jia Li   +27 more
wiley   +1 more source

Agenda (PDF)

open access: yes
Agenda for the 36th Annual Dept.
Obstetrics & Gynecology, Department of
core  

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah   +4 more
wiley   +1 more source

Unbound Intrinsic Formation Clearance of 6β‐Hydroxycortisol Is a Useful Biomarker of CYP3A4 Activity during Pregnancy

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pregnancy results in multiple physiological changes that impact drug disposition. For example, hepatic CYP3A activity and renal transporter‐mediated clearance increase in late pregnancy, but the time course of these changes across pregnancy is not known.
Aurora K Authement   +3 more
wiley   +1 more source

A 10-point framework for providing trauma-informed gynecological care for survivors of sexual violence: Human rights-based approach. [PDF]

open access: yesInt J Gynaecol Obstet
Familiar PP   +14 more
europepmc   +1 more source

Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pregnant and breastfeeding individuals are routinely excluded from clinical drug development, creating persistent evidence gaps in pharmacology, safety, and dosing. Despite mandatory contraception and pregnancy testing, unintended pregnancies occur, particularly during the development of central nervous system (CNS) medicines used by women of ...
Sam Schoenmakers   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy